CEL-SCI CORP
NYSE: CVM (Cel-Sci Corporation)
Kemas kini terakhir: semalam, 11:29PM1.21
-0.26 (-17.69%)
| Penutupan Terdahulu | 1.47 |
| Jumlah Dagangan | 879,800 |
| Purata Dagangan (3B) | 218,748 |
| Modal Pasaran | 21,282,676 |
| Harga / Buku (P/B) | 2.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Feb 2026 |
| EPS Cair (TTM) | -1.59 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 72.10% |
| Nisbah Semasa (MRQ) | 1.48 |
| Aliran Tunai Operasi (OCF TTM) | -16.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -8.91 M |
| Pulangan Atas Aset (ROA TTM) | -66.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -252.53% |
AISkor Stockmoo
| Nilai 30% | -3.8 |
| Pulangan di bawah kos modalnya. Pulangan atas modal menurun. info | |
| Hutang rendah. Keuntungan lemah. Aliran tunai negatif. info | |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa 30% | -4.4 |
| Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Aliran menurun, tetapi purata bergeraknya telah mendatar. Harga hampir dengan purata itu. Jatuh di bawah purata itu dengan dagangan tinggi. info | |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Corak Lilin info | NA |
| Sentimen 20% | 0.0 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Sentimen Pegangan info | NA |
| Sentimen Berita info | NA |
| Wang Pintar 20% | -0.5 |
| Institusi bersih -0.25% daripada saham dalam pemfailan 13F terkini: 22 pemegang menambah, 8 mengurang (suku berakhir 30 Sep 2026). info | |
| Aktiviti Orang Dalam info | NA |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak sependapat, jadi skor diperkukuh. | |
| Tidak dikira dalam skor | |
| Perolehan sesaham meningkat setiap tahun. Mencatat kerugian dalam tahun-tahun kebelakangan. info | |
| Di bawah garis aliran jangka sederhana. info | |
| Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info | |
| Harga hampir dengan paras sokongan. info | |
| Skor Akhir | -3.67 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Cel-Sci Corporation | - | - |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| CVM | 21 M | - | - | 2.22 | -3.7 |
| CYBN | 359 M | - | - | - | 0.0 |
| NRXS | 60 M | - | - | 18.58 | -1.2 |
| NHWK | 20 M | - | - | 0.260 | 0.0 |
| AEON | 10 M | - | - | - | -3.3 |
| TOVX | 6 M | - | 0.099 | 0.610 | -2.7 |
|
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 3.71% |
| % Dimiliki oleh Institusi | 14.60% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mai Capital Management | 30 Sep 2026 | 109,280 |
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 12.94%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 22 | 196,419 |
| Berkurang | 8 | 208,017 |
| Baharu | 7 | 29,620 |
| Dijual habis | 3 | 62,567 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Nov 2026 | Yahoo Finance |
CEL-SCI’s Multikine® Receives Saudi FDA NADR Designation, Accelerating Potential Commercial Launch
VIENNA, Va., November 20, 2026--CEL-SCI’s Multikine receives Saudi FDA NADR Designation, accelerating potential commercial launch. |
| 10 Nov 2026 | Yahoo Finance |
CEL-SCI’s Dr. Eyal Talor Receives Second International Keynote Invitation on Multikine Head and Neck Cancer Research
VIENNA, Va., November 10, 2026--CEL-SCI’s Dr. Eyal Talor receives second international keynote invitation on Multikine head and neck cancer research. |
| 29 Oct 2026 | Yahoo Finance |
CEL-SCI reports 73.4% five-year survival in Multikine Phase 3 patient analysis
CEL-SCI Corporation CEO Geert Kersten joined Steve Darling from Proactive to discuss new tumor-response and safety analyses from the company’s completed Phase 3 study of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy for head and neck cancer. The findings were… |
| 26 Oct 2026 | Yahoo Finance |
CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival
VIENNA, Va,, October 26, 2026--CEL-SCI presents Phase 3 Multikine data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival. |
| 15 Sep 2026 | Yahoo Finance |
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
VIENNA, Va., September 15, 2026--CEL-SCI invited to deliver keynote address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology. |
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |